FDA
-
-
-
-
-
-
-
Medincell: Half-Year Liquidity Contract Statement
-
-
-
-
-
-
-
PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors
-
-
-
-
-
-
-
Medincell raises €48 million in private placement
-
-
-
-
-
-
-
Medincell’s ISS ESG Corporate Rating Upgraded
-
-
-
-
-
-
-
Medincell Management to Present at the 8th Annual Evercore Healthcare Conference and at the Piper Sandler 37th Annual Healthcare Conference
-
-
-
-
-
-
-
FDA approves UZEDY for bipolar I disorder maintenance treatment
-
-
-
-
-
-
-
Medincell: New Pivotal Phase 3 Long-Term Data Supports Olanzapine Long-Acting Injectable (LAI) with Favorable Safety Profile – No PDSS Observed
-
333,560 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


